With regard to AMD3100, an inhibitor of CXCR4 that has been approved by the FDA for autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) due to its effect on neutrophil mobilization [58], further studies are needed to explore its potential preventative effect on neuroinflammation in PD through inhibition of CXCR4. The gene discussed is CXCR4; the disease is Miyoshi myopathy.